Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T82028 | ||||
Target Name | Sodium/hydrogen exchanger 1 (SLC9A1) | ||||
Type of Target |
Clinical trial |
||||
Drug Potency against Target | 5'-(N-ethyl-N-isopropyl)amiloride | Drug Info | IC50 = 800 nM | [3] | |
CARIPORIDE | Drug Info | IC50 = 65 nM | [4] | ||
ENIPORIDE | Drug Info | IC50 = 8 nM | [6] | ||
HOE-694 | Drug Info | IC50 = 130 nM | [5] | ||
N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine | Drug Info | IC50 = 270 nM | [5] | ||
N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine | Drug Info | IC50 = 210 nM | [5] | ||
N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | IC50 = 180 nM | [5] | ||
N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | IC50 = 380 nM | [5] | ||
N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | IC50 = 140 nM | [5] | ||
N-(5-m-Tolyl-furan-2-carbonyl)-guanidine | Drug Info | IC50 = 6000 nM | [1] | ||
N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine | Drug Info | IC50 = 150 nM | [5] | ||
N-(5-o-Tolyl-furan-2-carbonyl)-guanidine | Drug Info | IC50 = 340 nM | [1] | ||
N-(5-Phenyl-furan-2-carbonyl)-guanidine | Drug Info | IC50 = 3100 nM | [1] | ||
N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine | Drug Info | IC50 = 295 nM | [2] | ||
N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine | Drug Info | IC50 = 10000 nM | [2] | ||
N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine | Drug Info | IC50 = 1400 nM | [1] | ||
N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine | Drug Info | IC50 = 2300 nM | [1] | ||
References | |||||
REF 1 | (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. | ||||
REF 2 | Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-... Bioorg Med Chem Lett. 2007 May 1;17(9):2430-3. | ||||
REF 3 | NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous ... J Biol Chem. 2007 Jul 6;282(27):19716-27. | ||||
REF 4 | Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives. Eur J Med Chem. 2009 Sep;44(9):3771-6. | ||||
REF 5 | (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. | ||||
REF 6 | Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.